Arch Management Iv, L.L.C.J... Net Worth

The estimated Net Worth of Arch Management Iv, L.L.C.J... is at least 6.71 百万$ dollars as of 19 February 2014. Arch J owns over 103,500 units of Concert Pharmaceuticals Inc stock worth over 6,710,447$ and over the last 11 years Arch sold CNCE stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Arch J CNCE stock SEC Form 4 insiders trading

Arch has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Arch bought 103,500 units of CNCE stock worth 1,449,000$ on 19 February 2014.

The largest trade Arch's ever made was buying 103,500 units of Concert Pharmaceuticals Inc stock on 19 February 2014 worth over 1,449,000$. On average, Arch trades about 103,500 units every 0 days since 2014. As of 19 February 2014 Arch still owns at least 801,726 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Arch J stock trades at the bottom of the page.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over 69,766,120$ worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth 25,219,472$ . The most active insiders traders include Plc Gsk、Associates Gp Llcqvt Fund V...、Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of 447,820$. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth 50,380$.

What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Complete history of Arch J stock trades at Concert Pharmaceuticals Inc

Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Tung,
  President, Chief Executive Officer, Co-Founder, Director
• Nancy Stuart,
  Chief Operating Officer
• Marc Becker,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• James Cassella,
  Chief Development Officer
• Dr. Roger D. Tung,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. James V. Cassella,
  Chief Devel. Officer
• Jesper Hoiland,
  Independent Director
• Richard Aldrich,
  Independent Chairman of the Board, Co-Founder
• Thomas Auchincloss,
  Independent Director
• Ronald Barrett,
  Independent Director
• Peter Hutt,
  Independent Director
• Christine van Heek,
  Independent Director
• Wilfred Jaeger,
  Independent Director
• Richard H. Aldrich M.B.A., Mba,
  Co-Founder & Chairman
• Justine Koenigsberg,
  Senior Vice President, Corporate Communications and Investor Relations
• Jeffrey Munsie,
  Chief Legal Officer, Secretary
• Christine Boisclair,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Nabil Uddin Pharm.D.,
  VP of Corp. Devel.
• Jeffrey A. Munsie,
  Chief Legal Officer & Corp. Sec.
• Marc A. Becker,
  CFO & Principal Accounting Officer
• Nancy Stuart,
  Chief Operating Officer
• Wendall Wierenga,
  Director
• Wilfred Ethree Arch Managem...,
  
• Pauline Mc Gowan,
  VP, Finance
• D. Ryan Daws,
  Chief Financial Officer
• Robert Silverman,
  Senior VP, General Counsel
• Meghan Fitzgerald,
  Director
• Lynette Herscha,
  General Counsel
• Heek Christi Van,
  Director
• Ryan Lynch,
  PAO
• Partners L P/Ilbiotechnolog...,
  
• Leaf Ventures I, L.P.New Le...,
  
• Helmut Schuhsler,
  Director
• John Gordon Freund,
  Director
• Associates Gp Llcqvt Fund V...,
  
• Capital Management Llcbrook...,
  
• Ventures Fund 2004 L P Flag...,
  
• Plc Gsk,
  
• Capital Partners, L.P.Adage...,
  
• Venture Partners Qualified ...,
  
• Life Science Ventures Vi Gm...,
  
• Arch Management Iv, L.L.C.J...,
  
• Arch Management Iii Llcthre...,
  
• Arch Management Iv, L.L.C.J...,
  
• Xii Gp Llc Greylock Xii Lim...,
  
• Arch Management Iii Llcjaeg...,
  
• Jesper Hoeiland,
  Director
• Marc A. Becker,
  Chief Financial Officer